Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BrUOG 300: Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin

NCT02030574 is registered in ClinicalTrials.gov with Brown University as lead sponsor.

NCT NCT02030574
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02030574 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BrUOG 300: Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin
Lead sponsor
Brown University
Phase
Phase 2
Overall status
Terminated
Start date
July 31, 2014
Completion date
June 30, 2015
Enrollment
2 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, invasive bladder cancer